GILLIS STEVEN 4
4 · TAKEDA PHARMACEUTICAL CO LTD · Filed Jul 6, 2026
Research Summary
AI-generated summary of this filing
Takeda (TAK) Director Steven Gillis Receives RSU Award; Sells 1,152 Shares
What Happened
Steven Gillis, a director of Takeda Pharmaceutical (TAK), received equity awards and had a small disposition related to tax withholding. On 2026-07-01 he was granted RSU awards totaling 5,119 RSUs (3,800 RSUs + 1,319 RSUs) at $0 — each RSU is a contingent right to one Ordinary Share that will convert into American Depositary Shares (ADS) upon vesting. On 2026-07-10 there was a disposition to the issuer of 1,152 shares (reported as a derivative sale) at a weighted-average price of JPY 4,931.20 for total proceeds of JPY 5,680,742; footnotes indicate this sale was to cover tax obligations and any remaining proceeds were delivered to the reporting person.
Key Details
- Transaction dates: Grants on 2026-07-01; disposition to issuer on 2026-07-10.
- Grant specifics: 3,800 RSUs (F1) and 1,319 RSUs (derivative award), vesting noted as June 1, 2029 (F1).
- Sale specifics: 1,152 shares sold to issuer at weighted avg JPY 4,931.20 (range JPY 4,883–5,045) for JPY 5,680,742 (F4). Reporting person can provide per-price breakdown on request.
- Tax treatment: Footnotes describe “Tax Obligation Awards” — the economic equivalent of shares that are settled in cash primarily to cover taxes; remaining proceeds were delivered to the reporting person on July 10 (F3, F5).
- ADS conversion: Footnote F2 notes conversion of certain Ordinary Shares into ADS on vesting (example: 3,100 Ordinary Shares → 6,200 ADS).
- Shares owned after transaction: not disclosed in this filing.
- Filing timeliness: filing date 2026-07-06 for activity through 2026-07-10; the filing does not indicate a late filing flag.
Context: RSU grants are awards that give the holder a right to receive shares in the future (vesting dates apply) — they are not an immediate purchase. The July 10 disposition appears to be a routine, issuer-directed sale to satisfy tax withholding on vested awards (a cash settlement), which is common and not by itself a clear signal of the director’s view of the company.
Insider Transaction Report
- Award
Ordinary Shares
[F1][F2]2026-07-01+3,800→ 10,400 total - Disposition to Issuer
Tax Obligation Award
[F3][F4]2026-07-10$4931.20/sh−1,152$5,680,742→ 0 totalFrom: 2026-06-01Exp: 2026-06-01→ Ordinary Shares (1,152 underlying) - Award
Tax Obligation Award
[F5]2026-07-01+1,319→ 1,319 totalFrom: 2029-06-01Exp: 2029-06-01→ Ordinary Shares (1,319 underlying)
- 22,057
American Depositary Shares
[F2]
Footnotes (5)
- [F1]Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.
- [F2]Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs.
- [F3]Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10.
- [F4]The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.